Once analytics, pharmacokinetics, pharmacodynamics, and clinical trials confirm the clinical value and safety of the biosimilar, how does this translate into cost savings?

Once analytics, pharmacokinetics, pharmacodynamics, and clinical trials confirm the clinical value and safety of the biosimilar, how does this translate into cost savings?

Once robust analytics, pharmacokinetics, pharmacodynamics, and clinical trials confirm the clinical value and safety of the biosimilar, how does this translate into cost savings for patients and healthcare institutions?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Leonard Calabrese, DO

Leonard Calabrese, DO

Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Vice Chairman Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute